Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients can be classified into different categories with different therapeutic approaches and prognoses based on their age and clinical findings. Although most patients respond adequately to first-line treatments, a high unmet need exists for second-line agents that can be used in patients who do not respond to or cannot tolerate first-line therapy.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ET patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ET patients?
  • How has anagrelide (Agrylin) been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of ET patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
  • What percentage of ET patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

Table of contents

  • Essential Thrombocythemia - Current Treatment - Essential Thrombocythemia | Treatment Algorithms: Claims Data Analysis | US | Dashboard
    • About the Treatment Algorithms Dashboard
      • Dashboard

    Author(s): Kanika Ujla

    Kanika Ujla, M.S., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She conducts primary and secondary research in a range of antibacterial and antiviral indications, as well as numerous niche and rare diseases. She has experience in R&D, consulting, and business research with healthcare and life science companies. She obtained her master’s degree in biotechnology from the University of Jammu and her bachelor’s degree in biotechnology from Chaudhary Charan Singh University.